These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 32985295)

  • 1. Immunotherapy in advanced non-small-cell lung cancer with
    Liu F; Yuan X; Jiang J; Chu Q
    Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Clonal Neoantigens Derived From Driver Mutations in an
    Wu D; Liu Y; Li X; Liu Y; Yang Q; Liu Y; Wu J; Tian C; Zeng Y; Zhao Z; Xiao Y; Gu F; Zhang K; Hu Y; Liu L
    Front Immunol; 2020; 11():1366. PubMed ID: 32793190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the Efficacy of Immunotherapy on the Posterior Lines 
of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].
    Ma L; Qin N; Zhang X; Wu Y; Li H; Yu M; Liu Z; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):338-344. PubMed ID: 34034457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
    Ichihara E; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Cancer Immunol Immunother; 2021 Jan; 70(1):101-106. PubMed ID: 32648165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Real-world Study on the Expression Characteristics of PD-L1 in Patients 
with Advanced EGFR Positive NSCLC and Its Relationship with the 
Therapeutic Efficacy of EGFR-TKIs].
    Chen R; Gao X; Xu F; Zhang S; Ma L; Hu B
    Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):217-227. PubMed ID: 37035884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.
    Trabelsi Grati O; Zemoura L; Nhy C; Daniel C; Melaabi S; Callens C; Gauthier Villars M; Bièche I; Girard N
    Lung Cancer; 2022 Dec; 174():186-187. PubMed ID: 36156246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
    Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
    Liu Y; Miao J
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):934-942. PubMed ID: 38163979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
    Lin A; Wei T; Meng H; Luo P; Zhang J
    Mol Cancer; 2019 Sep; 18(1):139. PubMed ID: 31526368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors].
    Bai R; Chen N; Cui J
    Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):641-648. PubMed ID: 30172273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
    Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
    Front Immunol; 2022; 13():931718. PubMed ID: 35990690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 15. EGFR mutations induce the suppression of CD8
    Huang H; Zhu X; Yu Y; Li Z; Yang Y; Xia L; Lu S
    J Transl Med; 2024 Jul; 22(1):653. PubMed ID: 39004699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
    Yamada T; Hirai S; Katayama Y; Yoshimura A; Shiotsu S; Watanabe S; Kikuchi T; Hirose K; Kubota Y; Chihara Y; Harada T; Tanimura K; Takeda T; Tamiya N; Kaneko Y; Uchino J; Takayama K
    Cancer Med; 2019 Apr; 8(4):1521-1529. PubMed ID: 30790471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
    Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
    Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.